tiprankstipranks
Ocular Therapeutix announces over 300 subjects randomized in SOL-1
PremiumThe FlyOcular Therapeutix announces over 300 subjects randomized in SOL-1
3M ago
Ocular Therapeutix price target raised to $15 from $14 at H.C. Wainwright
Premium
The Fly
Ocular Therapeutix price target raised to $15 from $14 at H.C. Wainwright
3M ago
Ocular Therapeutix Reports Q3 2024 Financial Results
Premium
Company Announcements
Ocular Therapeutix Reports Q3 2024 Financial Results
3M ago
Ocular Therapeutix initiated with an Outperform at Scotiabank
PremiumThe FlyOcular Therapeutix initiated with an Outperform at Scotiabank
4M ago
Ocular Therapeutix management to meet with Piper Sandler
Premium
The Fly
Ocular Therapeutix management to meet with Piper Sandler
4M ago
Ocular announces accelerated timelines for SOL-1 registrational trial
Premium
The Fly
Ocular announces accelerated timelines for SOL-1 registrational trial
4M ago
Ocular Therapeutix price target lowered to $17 from $18 at Baird
PremiumThe FlyOcular Therapeutix price target lowered to $17 from $18 at Baird
7M ago
Ocular Therapeutix announces FDA feedback on Phase 3 SOL-R trial
Premium
The Fly
Ocular Therapeutix announces FDA feedback on Phase 3 SOL-R trial
7M ago
Ocular Therapeutix sees cash runway into 2028
Premium
The Fly
Ocular Therapeutix sees cash runway into 2028
7M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100